focus -WSS

focus

author：hotspot 2025-10-01 20:06:35 - browse：284

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： What to watch for from Zogenix and Amicus clinical trials

WSS

CDC Director Mandy Cohen on transparency, trust, and health

Ripples from Flovent's discontinuation is killing children with asthma

Search called off for baby washed away in Pennsylvania flash flood

The White House hikes tariffs on plastic syringes made in China

Lilly’s weekly insulin works as well as daily products, new studies show

Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

entertainment

focus

focus

ChatGPT in medicine: STAT answers readers' burning questions

Free medical tuition alone isn't enough to close gaps in primary care

In age of alternative facts, a scholarly course on calling out crap

WuXi Biologics beefs up its lobbying operation

At least 13 dead in Texas as scorching temps continue

Hottest summer in 2,000 years puts focus on extreme heat, health

The high cost of giving birth even with insurance

A new crop of companies is reshaping the health data economy

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

UHS says company favors patients whose insurance pays more

focus

New Alzheimer's drugs heat up race for early detection blood tests

The White House hikes tariffs on plastic syringes made in China

Roche’s Alnylam deal shows drug firms interested in heart drugs

Biogen says it will cut costs by $700 million, slash 1,000 jobs

UHS says company favors patients whose insurance pays more

Cherokee Nation medical school graduates its first class

knowledge

focus

focus

explore